Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong candidate for a significantly accelerated approval review.

Early weight loss of 2%-3% within 4 weeks is significantly linked to achieving clinically significant weight loss at 16 weeks among adults with obesity enrolled in commercial weight-loss programs.

Women using combined hormonal contraceptives lost less weight and had fewer restricted calories while involved in a behavioral weight loss program compared with controls, a presenter said at ObesityWeek.